Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1412582

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1412582

Hurthle Cell Carcinoma Treatment Market by Treatment (General Surgery, Radioactive Iodine, Robotic Surgery), End User (Ambulatory Surgical Center, Clinic, Hospital) - Global Forecast 2024-2030

PUBLISHED:
PAGES: 188 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & Online Access - 1 Year (Up to 5 User License)
USD 4949
PDF, Excel & Online Access - 1 Year (Enterprise User License)
USD 6969

Add to Cart

[188 Pages Report] The Hurthle Cell Carcinoma Treatment Market size was estimated at USD 6.44 billion in 2023 and expected to reach USD 6.82 billion in 2024, at a CAGR 6.41% to reach USD 9.96 billion by 2030.

Global Hurthle Cell Carcinoma Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 6.44 billion
Estimated Year [2024] USD 6.82 billion
Forecast Year [2030] USD 9.96 billion
CAGR (%) 6.41%
Hurthle Cell Carcinoma Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hurthle Cell Carcinoma Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hurthle Cell Carcinoma Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hurthle Cell Carcinoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company, Eurofins Scientific SE, Illumina Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer, Inc., Provell Pharmaceuticals, LLC, Qiagen N.V., Sanofi S.A., Sorrento Therapeutics, Inc., Teikoku Seiyaku Co. Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Hurthle Cell Carcinoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • General Surgery
    • Radioactive Iodine
    • Robotic Surgery
    • Total Thyroidectomy
  • End User
    • Ambulatory Surgical Center
    • Clinic
    • Hospital
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hurthle Cell Carcinoma Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hurthle Cell Carcinoma Treatment Market?

3. What are the technology trends and regulatory frameworks in the Hurthle Cell Carcinoma Treatment Market?

4. What is the market share of the leading vendors in the Hurthle Cell Carcinoma Treatment Market?

5. Which modes and strategic moves are suitable for entering the Hurthle Cell Carcinoma Treatment Market?

Product Code: MRR-0355054AC4AD

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Hurthle Cell Carcinoma Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing thyroid related diseases
      • 5.1.1.2. Rising healthcare awareness about necessity of treatment
      • 5.1.1.3. Increase in government initiatives
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of skilled professionals for the treatment of HCC
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological developments in HCC treatment
      • 5.1.3.2. Growing research and development activities of HCC treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects of the chemotherapy and lack of patient awareness
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Hurthle Cell Carcinoma Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. General Surgery
  • 6.3. Radioactive Iodine
  • 6.4. Robotic Surgery
  • 6.5. Total Thyroidectomy

7. Hurthle Cell Carcinoma Treatment Market, by End User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Center
  • 7.3. Clinic
  • 7.4. Hospital

8. Americas Hurthle Cell Carcinoma Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Hurthle Cell Carcinoma Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Hurthle Cell Carcinoma Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AbbVie Inc.
    • 12.1.2. Agilent Technologies, Inc.
    • 12.1.3. AstraZeneca PLC
    • 12.1.4. Bayer AG
    • 12.1.5. Eli Lilly and Company
    • 12.1.6. Eurofins Scientific SE
    • 12.1.7. Illumina Inc.
    • 12.1.8. Merck KGaA
    • 12.1.9. Novartis AG
    • 12.1.10. PerkinElmer, Inc.
    • 12.1.11. Pfizer, Inc.
    • 12.1.12. Provell Pharmaceuticals, LLC
    • 12.1.13. Qiagen N.V.
    • 12.1.14. Sanofi S.A.
    • 12.1.15. Sorrento Therapeutics, Inc.
    • 12.1.16. Teikoku Seiyaku Co. Ltd.
    • 12.1.17. Thermo Fisher Scientific Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
Product Code: MRR-0355054AC4AD

LIST OF FIGURES

  • FIGURE 1. HURTHLE CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HURTHLE CELL CARCINOMA TREATMENT MARKET DYNAMICS
  • FIGURE 7. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 10. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. HURTHLE CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. HURTHLE CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. HURTHLE CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 6. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROBOTIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TOTAL THYROIDECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 11. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. HURTHLE CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 101. HURTHLE CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. HURTHLE CELL CARCINOMA TREATMENT MARKET LICENSE & PRICING
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!